[1]陈美慧 韩宇博 隋艳波 樊德慧 张丹丹 王瑞楠?刘莉.铁代谢与心力衰竭关系的研究进展[J].心血管病学进展,2022,(1):23-25.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.006]
 CHEN Meihui,HAN Yubo,SUI Yanbo,et al.The Relationship Between Iron Metabolism and Heart Failure[J].Advances in Cardiovascular Diseases,2022,(1):23-25.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.006]





The Relationship Between Iron Metabolism and Heart Failure
陈美慧1 韩宇博 2 隋艳波 2 樊德慧 1 张丹丹1 王瑞楠?刘莉2
(1.黑龙江中医药大学,黑龙江 哈尔滨 150040;2.黑龙江中医药大学附属第一医院心血管科科,黑龙江 哈尔滨 150040)
CHEN Meihui 1HAN Yubo 2SUI Yanbo 2FAN Dehui1ZHANG Dandan1WANG Ruinan1LIU Li 2
(1.Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang,China2.Department of Cardiology,The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang,China)
Heart failureIron metabolismIron deficiencyIron overload
Heart failure(HF) is the terminal stage of heart disease caused by various causes. It is a common disease in modern society,and has high morbidity and mortality. Iron is one of the essential trace elements in human body. It exists in liver,spleen,kidney,heart,skeletal muscle,brain and other tissues in the form of ions. It is widely involved in various physiological activities of human body,and the iron metabolic balance is an important part of maintaining human life activities. A number of studies have found that there is a certain relationship between iron metabolism and HF,which affects the disease progression and prognosis of patients with HF. This paper reviews the research progress of the relationship between iron metabolism and HF,providing new ideas for the prevention and treatment of HF from the perspective of iron metabolism.


[1] Silvestre OM,Gon?alves A,Nadruz W Jr,et al. Ferritin levels and risk of heart failure —the Atherosclerosis Risk in Communities Study[J]. Eur J Heart Fail,2017,19(3):340-347.

[2] 邓英建,郑小燕,涂涛,等. 铁超负荷性心肌病一例[J]. 中华心血管病杂志,2018,46(3):225-227.

[3] Beattie JM,Khatib R,Phillips CJ,et al. Iron deficiency in 78 805 people admitted with heart failure across England:a retrospective cohort study[J]. Open Heart,2020,7(1):e001153.

[4] Zusman O,Itzhaki Ben Zadok O,Gafter-Gvili A. Management of iron deficiency in heart failure[J]. Acta Haematol,2019,142(1):51-56.

[5] 中国医师协会心力衰竭专业委员会,国家心血管病专家委员会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 中国心力衰竭患者离子管理专家共识[J]. 中华心力衰竭和心肌病杂志,2020,4(1):16-31.

[6] Mordi IR,Tee A,Lang CC. Iron therapy in heart failure:ready for primetime?[J]. Card Fail Rev,2018,4(1):28-32.

[7] Lam CSP,Doehner W,Comin-Colet J,et al. Iron deficiency in chronic heart failure:case-based practical guidance[J]. ESC Heart Fail,2018,5(5):764-771.

[8] Kobak KA,Radwańska M,Dzi?ga?a M,et al. Structural and functional abnormalities in iron-depleted heart[J].?Heart Fail Rev,2019,24(2):269-277.

[9] Dong F,Zhang X,Culver B,et al. Dietary iron deficiency induces ventricular dilation,mitochondrial ultrastructural aberrations and cytochrome c release:involvement of nitric oxide synthase and protein tyrosine nitration[J]. Clin Sci (Lond),2005,109(3):277-286.

[10] Chung YJ,Swietach P,Curtis MK,et al. Iron-deficiency anemia results in transcriptional and metabolic remodeling in the heart toward a glycolytic phenotype[J]. Front Cardiovasc Med,2021,7:616920.

[11] Hoes MF,Grote Beverborg N,Kijlstra JD,et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function[J].Eur J Heart Fail,2018,20(5):910-919.

[12] Haddad S,Wang Y,Galy B,et al. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure[J]. Eur Heart J,2017,38(5):362-372.

[13] Ponikowski P,v an Veldhuisen DJ,Comin-Colet J,et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency dagger[J]. Eur Heart J,2015,36(11):657-668.

[14] Klip IT,Voors AA,Swinkels DW,et al. Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community[J]. Eur J Heart Fail,2017,19(3):348-356.

[15] Anand IS,Gupta P. Anemia and iron deficiency in heart failure:current concepts and emerging therapies[J].?Circulation,2018,138(1):80-98.

[16] Lewis GD,Malhotra R,Hernandez AF,et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency:the IRONOUT HF randomized clinical trial[J]. JAMA,2017, 317(19):1958-1966.

[17] Liu B,Zhao C,Li H,et al. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis[J].?Biochem Biophys Res Commun,2018,497(1):233-240.

[18] Girelli D,Nemeth E,Swinkels DW. Hepcidin in diagnosis of iron disorders[J]. Blood,2016,127(23):2809-2813.

[19] Hentze MW,Muckenthaler MU,Galy B,et al. Two to tango:regulation of mammalian iron metabolism[J]. Cell,2010,142(1):24-38.

[20] Solomakhina NI,Nakhodnova ES,Gitel EP,et al. Hepcidin and its relationship with inflammation in old and older patients with anemia of chronic disease associated with CHF[J]. Kardiologiia,2018(S2):4-11.

[21] Kanamori Y,Murakami M,Sugiyama M,et al. Interleukin-1β(IL-1β) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein δ (C/EBPδ) expression in hepatocytes[J].?J Biol Chem,2017,292(24):10275-10287.

[22] Kanamori Y,Murakami M,Matsui T,et al. JNK facilitates IL-1β-induced hepcidin transcription via JunB activation[J].?Cytokine,2018,111:295-302.

[23] Stockwell BR,Friedmann Angeli JP,Bayir H,et al. Ferroptosis:a regulated cell death nexus linking metabolism,redox biology,and disease[J]. Cell,2017,171(2):273-285.

[24] Dixon SJ,Lemberg KM,Lamprecht MR,et al. Ferroptosis:an iron-dependent form of nonapoptotic cell death[J].?Cell,2012,149(5):1060-1072.

[25] Yang WS,Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol,2008,15(3):234-245.

[26] Valko M,Jomova K,Rhodes CJ,et al. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease[J].?Arch Toxicol,2016,90(1):1-37.

[27] Wang J,Deng B,Liu Q,et al. Pyroptosis and ferroptosis induced by mixed lineage kinase 3(MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload[J].?Cell Death Dis,2020,11(7):574.

[28] 季春影,张瑞英. 心力衰竭与心肌线粒体代谢[J]. 心血管病学进展,2020,41(1):63-66.

[29] Gao M,Yi J,Zhu J,et al. Role of mitochondria in ferroptosis[J].?Mol Cell,2019,73(2):354-363.

[30] Qi Z,Chen L. Endoplasmic reticulum stress and autophagy[J].?Adv Exp Med Biol,2019,1206:167-177.

[31] So JS. Roles of endoplasmic reticulum stress in immune responses[J].?Mol Cells,2018,41(8):705-716.

[32] Wang X,Xu L,Gillette TG,et al. The unfolded protein response in ischemic heart disease[J].?J Mol Cell Cardiol,2018,117:19-25.

[33] Binder P,Wang S,Radu M,et al. Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response[J].?Circ Res ,2019,124(5):696-711.

[34] Li W,Li W,Leng Y,et al. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress[J].?DNA Cell Biol,2020,39(2):210-225.


 DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
 LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(1):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
 ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
 LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(1):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
 KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(1):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
 SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(1):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
 XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
 GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(1):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
 HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
 WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]王文杰 杨嘉馨 丁耀东 王可馨 牛佳龙 葛海龙.铁死亡在心血管疾病中的研究进展[J].心血管病学进展,2023,(5):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]
 WANG Wenjie,YANG Jiaxin,DING Yaodong,et al.Ferroptosis in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(1):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]

更新日期/Last Update: 2022-02-17